Eli Lilly pays $115m upfront for AI drug pipeline in $2.75bn Insilico deal

Back to home

Share

M&A

2 min read

|

Updated 1 month ago

|

$LLY $3696.HK

Briefing

Eli Lilly has signed a collaboration agreement with Hong Kong-listed Insilico Medicine, paying $115 million upfront for an exclusive worldwide licence to a portfolio of AI-generated drug programmes across multiple therapeutic areas. The deal carries total potential value of up to $2.75 billion, with the bulk contingent on development, regulatory and commercial milestones. The agreement also includes Lilly accessing Insilico's generative AI platform for ongoing research and development work.

Eli Lilly and Insilico Medicine: Deal Structure

Eli Lilly has agreed a global research and development collaboration with Insilico Medicine, the clinical-stage biotechnology company listed on the Hong Kong Stock Exchange, in a deal that could be worth up to $2.75 billion in total, according to announcements from both companies.

The immediate cash consideration is $115 million, paid upfront by Lilly for an exclusive worldwide licence to Insilico's early-stage drug pipeline spanning multiple therapeutic areas. The remaining $2.63 billion is structured as milestone payments tied to development, regulatory and commercial outcomes, meaning the headline figure is achievable only if the licensed programmes advance successfully through trials and reach the market.

Beyond the licence, the agreement covers ongoing R&D collaboration in which Lilly will draw on Insilico's generative AI platform for drug discovery work. Insilico has positioned itself as an AI-native drug developer, using its platform to identify targets and generate candidate molecules, a process it argues compresses the early stages of drug development.

The deal represents a meaningful validation of AI-driven drug discovery by one of the pharmaceutical industry's largest companies. Lilly, whose chief commercial focus has been on obesity and diabetes drugs, is using the collaboration to expand its early-stage pipeline through an asset-light arrangement that limits upfront capital exposure while retaining optionality across several disease areas.

Insilico is a Cambridge, Massachusetts-based company that trades under the ticker 3696 on the HKEX. Its lead programme, an AI-designed drug for idiopathic pulmonary fibrosis, is already in clinical trials, giving Lilly some visibility on the platform's ability to produce clinically viable candidates.

The transaction was first reported by the Financial Times on March 29, 2026, which cited a figure of approximately $2 billion; the confirmed deal value of $2.75 billion exceeded that initial report.

Analysis

The $2.75bn deal, even at $115m upfront, sets a valuation comp for AI-native drug discovery platforms that reprices the entire sector. Recursion Pharmaceuticals, Schrodinger, and Exscientia are the most direct beneficiaries, as large-cap pharma business development teams will now benchmark AI pipeline licensing against this structure. Expect multiple expansion in RXRX and SDGR on deal announcement day and sustained elevation as buyer competition among Pfizer, AstraZeneca, and Roche increases for the remaining independent AI drug discovery assets.
For Lilly specifically, the deal signals that its post-GLP-1 diversification is accelerating via external pipeline rather than purely internal R&D. The milestone-heavy structure limits near-term EPS dilution while securing pipeline optionality, which is exactly what buy-side models need to justify LLY's roughly $700bn market cap once tirzepatide and retatrutide face generic competition. The transaction modestly de-risks LLY's medium-term revenue cliff and gives analysts a concrete pipeline-building narrative to refresh price targets.

Connected Events

M&A · 2 months ago

Merck buys Terns Pharmaceuticals for $6.7bn to shore up post-Keytruda pipeline

Merck's $6.7bn acquisition of Terns Pharmaceuticals to address the Keytruda patent cliff reflects the same large-cap pharma pipeline anxiety driving Lilly toward Insilico. Both deals confirm that the largest pharmaceutical companies are willing to pay premium structures for external pipeline, with Merck buying late-stage clinical assets and Lilly buying AI-generated early-stage candidates. The combined signal is that BD valuations across the biotech spectrum are structurally supported regardless of clinical stage.

Eli Lilly and Insilico Medicine: Deal Structure

Analysis

Connected Events

Merck buys Terns Pharmaceuticals for $6.7bn to shore up post-Keytruda pipeline

Further reading

Related Stories

James Murdoch's Lupa Systems acquires Vox, New York Magazine and podcast network for $300m

Google and Blackstone to form AI cloud joint venture with $5bn backing

Eli Lilly pays $115m upfront for AI drug pipeline in $2.75bn Insilico deal

Meta to cut 8,000 jobs and reassign 7,000 to AI roles in restructuring beginning May 20